Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COATED-AIR: Aspirin Formulations and Air Pollution Strategy in ASCVD
NCT06541691Recruiting
- Sponsor
- Rajaie Cardiovascular Medical and Research Center
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of aspirin in atherosclerotic cardiovascular disease (ASCVD) (4 arms), sponsored by Rajaie Cardiovascular Medical and Research Center. Primary endpoints: Composite of fatal or nonfatal ischemic stroke, type I myocardial infarction, and acute limb events at 30 months and Composite of non-fatal ischemic stroke, type I myocardial infarction, acute limb events, or cardiovascular death at 30 months. Started Mar 2024; status: recruiting.
02
Drugs
aspirin
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT06541691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06541691.